Pharmacokinetics-pharmacology disconnection of herbal medicines and its potential solutions with cellular pharmacokinetic-pharmacodynamic strategy

Current Drug Metabolism

Volumn 13, Issue 5, 2012, Pages 558-576

  Zhang, Jingwei ^a   Zhou, Fang ^a   Lu, Meng ^a   Ji, Wei ^a   Niu, Fang ^a   Zha, Weibin ^a   Wu, Xiaolan ^a   Hao, Haiping ^a   Wang, Guangji ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Cellular pharmacokinetics pharmacodynamics; Drug transporter; Herbal medicines; Metabolic enzyme; Pharmacokinetics pharmacology disconnection; Subcellular distribution

Indexed keywords

3 (3,4 DIHYDROXYPHENYL)LACTIC ACID; ANTINEOPLASTIC AGENT; ARTEMISININ; BERBERINE; CAMPTOTHECIN; CRYPTOTANSHINONE; DIHYDROTANSHINONE; DOXORUBICIN; GINSENG EXTRACT; GINSENOSIDE RB 1; GINSENOSIDE RD; GINSENOSIDE RG 1; GINSENOSIDE RG 3; GINSENOSIDE RH 2; PACLITAXEL; PROTOCATECHUALDEHYDE; QUININE; ROSMARINIC ACID; SALVIA MILTIORRHIZA EXTRACT; TANSHINONE I; TANSHINONE IIA; TANSHINONE IIB; TERPENOID; UNCLASSIFIED DRUG;

ARTICLE; CELLULAR DISTRIBUTION; DRUG TRANSPORT; ENZYME METABOLISM; GINSENG; HERBAL MEDICINE; HUMAN; MEDICAL RESEARCH; NONHUMAN; PHARMACODYNAMICS; RETROSPECTIVE STUDY; SALVIA MILTIORRHIZA;

EID: 84861907787     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200211209050558     Document Type: Article

References (351)

1. Bent, S. Herbal medicine in the United States: review of efficacy, safety, and regulation: grand rounds at University of California, San Francisco Medical Center. J. Gen. Intern. Med., 2008, 23 (6),854-859.
2. Ernst, E.; Pittler, M.H. Herbal medicine. Med. Clin. North. Am., 2002, 86 (1),149-161.
3. Dwyer, A.V.; Whitten, D.L.; Hawrelak, J.A. Herbal medicines, other than St. John's Wort, in the treatment of depression: a systematic review. Altern. Med. Rev., 2011, 16 (1),40-49.
4. Feucht, C.; Patel, D.R. Herbal medicines in pediatric neuropsychiatry. Pediatr. Clin. North. Am., 2011, 58 (1),33-54.
5. Omar, E.A.; Kam. A.; Alqahtani, A.; Li, K.M.; Razmovski- Naumovski, V.; Nammi, S.; Chan, K.; Roufogalis, B.D.; Li, G.Q. Herbal medicines and nutraceuticals for diabetic vascular complications: mechanisms of action and bioactive phytochemicals. Curr. Pharm. Des., 2010, 16 (34),3776-3807.
6. De Smet P.A. Herbal remedies. N. Engl. J. Med., 2002, 347 (25),2046-2056.
7. Zhou, S.F.; Xue, C.C.; Yu, X.Q.; Wang, G. Metabolic activation of herbal and dietary constituents and its clinical and toxicological implications: an update. Curr. Drug Metab., 2007, 8 (6),526-553.
8. He, S.M.; Li, C.G.; Liu, J.P.; Chan, E.; Duan, W.; Zhou, S.F. Disposition pathways and pharmacokinetics of herbal medicines in humans. Curr. Med. Chem., 2010, 17 (33),4072-4113.
9. Skalicka-Wozniak, K.; Ludwiczuk, A.; Widelski, J.; Filipe, J.J.; Asakawa, Y.; Glowniak, K. Volatile constituents of Ocimum minimum herb cultivated in Portugal. Nat. Prod. Commun., 2009, 4 (10),1383-1386.
10. Ernst E. The current position of complementary/alternative medicine in cancer. Eur. J. Cancer, 2003, 39 (16),2273-2277.
11. Jordan, S.A.; Cunningham, D.G.; Marles, R.J. Assessment of herbal medicinal products: challenges, and opportunities to increase the knowledge base for safety assessment. Toxicol. Appl. Pharmacol., 2010, 243 (2),198-216.
12. He, S.M.; Chan, E.; Zhou, S.F. ADME properties of herbal medicines in humans: evidence, challenges and strategies. Curr. Pharm. Des., 2011, 17 (4),357-407.
13. Cohen, P.A.; Ernst, E. Safety of herbal supplements: a guide for cardiologists. Cardiovasc. Ther., 2010, 28 (4),246-253.
14. Tarirai, C.; Viljoen, A.M.; Hamman, J.H. Herb-drug pharmacokinetic interactions reviewed. Expert. Opin. Drug Metab. Toxicol., 2010, 6 (12),1515-1538.
15. Kang, A.; Hao, H.; Zheng, X.; Liang, Y.; Xie, Y.; Xie, T.; Dai, C.; Zhao, Q.; Wu, X.; Xie, L.; Wang, G. Peripheral anti-inflammatory effects explain the ginsenosides paradox between poor brain distribution and anti-depression efficacy. J. Neuroinflammation, 2011, 8,100.
16. Johnson, D.E.; Braeckman, R.A.; Wolfgang, G.H. Practical aspects of assessing toxicokinetics and toxicodynamics. Curr. Opin. Drug Discov. Devel., 1999, 2 (1),49-57.
17. Bayliss, M.K.; Frick, L.W. High-throughput pharmacokinetics: cassette dosing. Curr. Opin. Drug Discov. Devel., 1999, 2 (1),20-25.
18. Humphrey, M.J. Application of metabolism and pharmacokinetic studies to the drug discovery process. Drug Metab. Rev., 1996, 28 (3),473-489.
19. Todd, M.D.; Ulrich, R.G. Emerging technologies for accelerated toxicity evaluation of potential drug candidates. Curr. Opin. Drug Discov. Devel., 1999, 2 (1),58-68.
20. Tarbit, M.H.; Berman, J. High-throughput approaches for evaluating absorption, distribution, metabolism and excretion properties of lead compounds. Curr. Opin. Chem. Biol., 1998, 2 (3),411-416.
21. Smith, D.A.; van de, Waterbeemd H. Pharmacokinetics and metabolism in early drug discovery. Curr. Opin. Chem. Biol., 1999, 3 (4),373-378.
22. Sinko, P.J. Drug selection in early drug development: screening for acceptable pharmacokinetic properties using combined in vitro and computational approaches. Curr. Opin. Drug Discov. Devel., 1999, 2 (1),42-48.
23. Watanabe, T.; Ohnuki, K.; Kobata, K. Studies on the metabolism and toxicology of emerging capsinoids. Expert. Opin. Drug Metab. Toxicol., 2011, 7 (5),533-542.
24. Amacher, D.E. Strategies for the early detection of drug-induced hepatic steatosis in preclinical drug safety evaluation studies. Toxicology, 2011, 279 (1-3),10-18.
25. DiMasi, J.A. Success rates for new drugs entering clinical testing in the United States. Clin. Pharmacol. Ther., 1995, 58 (1),1-14.
26. Prentis, R.A.; Lis, Y.; Walker, S.R. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br. J. Clin. Pharmacol., 1988, 25 (3),387-396.
27. Kennedy, T. Managing the drug discovery/development interface. Drug Discov. Today, 1997, 2 (10),436-444.
28. Kola, I.; Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov., 2004, 3 (8),711-715.
29. Hodgson, J. ADMET - turning chemicals into drugs. Nat. Biotechnol., 2001, 19 (8),722-726.
30. Rawlins, M.D. Cutting the cost of drug development? Nat. Rev. Drug Discov., 2004, 3 (4),360-364.
31. Walker, D.K. The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development. Br. J. Clin. Pharmacol., 2004, 58 (6),601-608.
32. Derendorf, H.; Meibohm, B. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharmaceut. Res., 1999, 16 (2),176-185.
33. Qiu, J. China plans to modernize traditional medicine. Nature, 2007, 446 (7136),590-591.
34. Hao, H.; Cui, N.; Wang, G.; Xiang, B.; Liang, Y.; Xu, X.; Zhang, H.; Yang, J.; Zheng, C.; Wu, L.; Gong, P.; Wang, W. Global detection and identification of nontarget components from herbal preparations by liquid chromatography hybrid ion trap time-of-flight mass spectrometry and a strategy. Anal. Chem., 2008, 80 (21),8187-8194.
35. Liang, Y.; Hao, H.; Xie, L.; Kang, A.; Xie, T.; Zheng, X.; Dai, C.; Hao, K.; Sheng, L.; Wang, G. Development of a systematic approach to identify metabolites for herbal homologs based on liquid chromatography hybrid ion trap time-of-flight mass spectrometry: rats. Drug Metab. Dispos., 2010, 38 (10),1747-1759.
36. Liang, Y.; Hao, H.; Kang, A.; Xie, L.; Xie, T.; Zheng, X.; Dai, C.; Wan, L.; Sheng, L.; Wang, G. Qualitative and quantitative determination of complicated herbal components by liquid chromatography hybrid ion trap time-of-flight mass spectrometry and a relative exposure approach to herbal pharmacokinetics independent of standards. J. Chromatogr. A., 2010, 1217 (30), 4971-4979.
37. Lu, T.; Yang, J.; Gao, X.; Chen, P.; Du, F.; Sun, Y.; Wang, F.; Xu, F.; Shang, H.; Huang, Y.; Wang, Y.; Wan, R.; Liu, C.; Zhang, B.; Li, C. Plasma and urinary tanshinol from Salvia miltiorrhiza (Danshen) can be used as pharmacokinetic markers for cardiotonic pills, a cardiovascular herbal medicine. Drug Metab. Dispos., 2008, 36 (8),1578-1586.
38. Aa, J.Y.; Wang, G.J.; Hao, H.P.; Huang, Q.; Lu, Y.H.; Yan, B.; Zha, W.B.; Liu, L.S.; Kang, A. Differential regulations of blood pressure and perturbed metabolism by total ginsenosides and conventional antihypertensive agents in spontaneously hypertensive rats. Acta. Pharmacol. Sin., 2010, 31 (8),930-937.
39. Coon, J.T.; Ernst, E. Andrographis paniculata in the treatment of upper respiratory tract infections: a systematic review of safety and efficacy. Planta Med., 2004, 70 (4),293-298.
40. Ye, L.; Wang, T.; Tang, L.; Liu, W.; Yang, Z.; Zhou, J.; Zheng, Z.; Cai, Z.; Hu, M.; Liu, Z. Poor oral bioavailability of a promising anticancer agent andrographolide is due to extensive metabolism and efflux by P-glycoprotein. J. Pharm. Sci., 2011, 100(11), 5007-5017
41. Jarukamjorn, K.; Don-in, K.; Makejaruskul, C.; Laha, T.; Daodee, S.; Pearaksa, P.; Sripanidkulchai B.O. Impact of Andrographis paniculata crude extract on mouse hepatic cytochrome P450 enzymes. J. Ethnopharmacol., 2006, 105 (3),464-467.
42. Jaruchotikamol, A.; Jarukamjorn, K.; Sirisangtrakul, W.; Sakuma, T.; Kawasaki, Y.; Nemoto N. Strong synergistic induction of CYP1A1 expression by andrographolide plus typical CYP1A inducers in mouse hepatocytes. Toxicol. Appl. Pharmacol., 2007, 224 (2), 156-162.
43. Junyaprasert, V.B.; Soonthornchareonnon, N.; Thongpraditchote, S.; Murakami, T.; Takano, M. Inhibitory effect of Thai plant extracts on P-glycoprotein mediated efflux. Phytother. Res., 2006, 20 (1),79-81.
44. Efferth, T.; Herrmann, F.; Tahrani, A.; Wink, M. Cytotoxic activity of secondary metabolites derived from Artemisia annua L. towards cancer cells in comparison to its designated active constituent artemisinin. Phytomedicine, 2011, 18 (11),959-969.
45. Navaratnam, V.; Mansor, S.M.; Sit, N.W.; Grace, J.; Li, Q.; Olliaro, P. Pharmacokinetics of artemisinin-type compounds. Clin. Pharmacokinet., 2000, 39 (4),255-270.
46. Liu, Q.; Liu, S.N.; Li, L.Y.; Chen, Z.Y.; Lei, L.; Zhang, N.; Shen, Z.F. A dyslipidemia animal model induced by poloxamer 407 in golden hamsters and pilot study on the mechanism. Yao. Xue. Xue. Bao., 2011, 46 (4),406-411.
47. Burk, O.; Arnold, K.A.; Nussler, A.K.; Schaeffeler, E.; Efimova, E.; Avery, B.A.; Avery, M.A.; Fromm M.F.; Eichelbaum M. Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol. Pharmacol., 2005, 67 (6),1954-1965.
48. Riganti, C.; Doublier, S.; Viarisio, D.; Miraglia, E.; Pescarmona, G.; Ghigo, D.; Bosia, A. Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glycoprotein overexpression. Br. J. Pharmacol., 2009, 156 (7),1054-1066.
49. Aggarwal, B.B.; Sung, B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends. Pharmacol. Sci., 2009, 30 (2),85-94.
50. Aggarwal, B.B.; Harikumar, K.B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell Biol., 2009, 41 (1),40-59.
51. Goel, A.; Kunnumakkara, A.B.; Aggarwal, B.B. Curcumin as "Curecumin": from kitchen to clinic. Biochem. Pharmacol., 2008, 75 (4),787-809.
52. Cheng, A.L.; Hsu, C.H.; Lin, J.K.; Hsu, M.M.; Ho, Y.F.; Shen, T.S.; Ko, J.Y.; Lin, J.T.; Lin, B.R.; Ming-Shiang, W.; Yu, H.S.; Jee, S.H.; Chen, G.S.; Chen, T.M.; Chen, C.A.; Lai, M.K.; Pu, Y.S.; Pan, M.H.; Wang, Y.J.; Tsai, C.C.; Hsieh, C.Y. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res., 2001, 21 (4B),2895-2900.
53. Lao, C.D.; Ruffin, M.T.t.; Normolle, D.; Heath, D.D.; Murray, S.I.; Bailey, J.M.; Boggs, M.E.; Crowell, J.; Rock, C.L.; Brenner, D.E. Dose escalation of a curcuminoid formulation. BMC. Complement. Altern. Med., 2006, 6,10.
54. Ireson, C.R.; Jones, D.J.; Orr, S.; Coughtrie, M.W.; Boocock, D.J.; Williams, M.L.; Farmer, P.B.; Steward, W.P.; Gescher, A.J. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer. Epidemiol. Biomarkers. Prev., 2002, 11 (1),105-111.
55. Mach, C.M.; Chen, J.H.; Mosley, S.A.; Kurzrock, R.; Smith, J.A. Evaluation of liposomal curcumin cytochrome p450 metabolism. Anticancer Res., 2010, 30 (3),811-814.
56. Juan, H.; Terhaag, B.; Cong, Z.; Bi-Kui, Z.; Rong-Hua, Z.; Feng, W.; Fen-Li, S.; Juan, S.; Jing, T.; Wen-Xing, P. Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers. Eur. J. Clin. Pharmacol., 2007, 63 (7),663-668.
57. Wortelboer, H.M.; Usta, M.; van der Velde, A.E.; Boersma, M.G.; Spenkelink, B.; van Zanden, J.J.; Rietjens, I.M.; van Bladeren, P.J.; Cnubben, N.H. Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin. Chem. Res. Toxicol., 2003, 16 (12),1642-1651.
58. Ebert, B.; Seidel, A.; Lampen, A. Phytochemicals induce breast cancer resistance protein in Caco-2 cells and enhance the transport of benzo[a]pyrene-3-sulfate. Toxicol. Sci., 2007, 96 (2),227-236.
59. Wang, J.W.; Wu, J.Y. Tanshinone biosynthesis in Salvia miltiorrhiza and production in plant tissue cultures. Appl. Microbiol. Biotechnol., 2010, 88 (2),437-449.
60. Li, J.; Wang, G.; Li P.; Hao, H. Simultaneous determination of tanshinone IIA and cryptotanshinone in rat plasma by liquid chromatography- electrospray ionisation-mass spectrometry. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 2005, 826 (1-2),26-30.
61. Qiu, F.; Zhang, R.; Sun, J.; Jiye, A.; Hao, H.; Peng, Y.; Ai, H.; Wang, G. Inhibitory effects of seven components of danshen extract on catalytic activity of cytochrome P450 enzyme in human liver microsomes. Drug Metab. Dispos., 2008, 36 (7),1308-1314.
62. Ueng, Y.F.; Kuo, Y.H.; Wang, S.Y.; Lin, Y.L.; Chen, C.F. Induction of CYP1A by a diterpene quinone tanshinone IIA isolated from a medicinal herb Salvia miltiorrhiza in C57BL/6J but not in DBA/2J mice. Life Sci., 2004, 74 (7),885-896.
63. Lee, J.H.; Shin, Y.J.; Kim, H.J.; Oh, J.H.; Jang, Y.P.; Lee, Y.J. Danshen extract does not alter pharmacokinetics of docetaxel and clopidogrel, reflecting its negligible potential in P-glycoproteinand cytochrome P4503A-mediated herb-drug interactions. Int. J. Pharm., 2011, 410 (1-2),68-74.
64. Ballero, M.; Foddis, C.; Sanna, C.; Scartezzini, P.; Poli, F.; Petitto, V.; Serafini, M.; Stanzione, A.; Bianco, A.; Serilli, A.M.; Spina, L.; Longoni, R.; Kasture, S. Pharmacological activities on Ephedra nebrodensis Tineo. Nat. Prod. Res., 2010, 24 (12),1115-1124.
65. Gurley, B.J.; Gardner, S.F.; White, L.M.; Wang, P.L. Ephedrine pharmacokinetics after the ingestion of nutritional supplements containing Ephedra sinica (ma huang). Ther. Drug Monit., 1998, 20 (4),439-445.
66. Woolf, A.D.; Watson, W.A.; Smolinske, S.; Litovitz, T. The severity of toxic reactions to ephedra: comparisons to other botanical products and national trends from 1993-2002. Clin. Toxicol. (Phila), 2005, 43 (5),347-355.
67. Naik, S.D.; Freudenberger, R.S. Ephedra-associated cardiomyopathy. Ann. Pharmacother., 2004, 38 (3),400-403.
68. Tang, J.; Zhou, X.; Ji, H.; Zhu, D.; Wu, L. Effects of Ephedra Water Decoction and Cough Tablets containing Ephedra and Liquorice on CYP1A2 and the Pharmacokinetics of Theophylline in Rats. Phytother. Res., 2012, 26(3),470-474.
69. Lu, Y.; Chen, D.F. Analysis of Schisandra chinensis and Schisandra sphenanthera. J. Chromatogr. A., 2009, 1216 (11),1980-1990.
70. Cao, Y.F.; Zhang, Y.Y.; Li, J.; Ge, G.B.; Hu, D.; Liu, H.X.; Huang, T.; Wang, Y.C.; Fang, Z.Z.; Sun, D.X.; Huo, H.; Yin, J.; Yang, L. CYP3A catalyses schizandrin biotransformation in human, minipig and rat liver microsomes. Xenobiotica., 2010, 40 (1),38-47.
71. Wan, C.K.; Tse, A.K.; Yu, Z.L.; Zhu, G.Y.; Wang, H.; Fong, D.W. Inhibition of cytochrome P450 3A4 activity by schisandrol A and gomisin A isolated from Fructus Schisandrae chinensis. Phytomedicine, 2010, 17 (8-9),702-705.
72. Fong, W.F.; Wan, C.K.; Zhu, G.Y.; Chattopadhyay, A.; Dey, S.; Zhao, Z.; Shen, X.L. Schisandrol A from Schisandra chinensis reverses P-glycoprotein- mediated multidrug resistance by affecting Pgp-substrate complexes. Planta Med., 2007, 73 (3),212-220.
73. Ginter, E.; Simko V. Garlic (Allium sativum L.) and cardiovascular diseases. Bratisl. Lek. Listy., 2010, 111 (8),452-456.
74. Kaschula, C.H.; Hunter, R.; Parker, M.I. Garlic-derived anticancer agents: structure and biological activity of ajoene. Biofactors, 2010, 36 (1),78-85.
75. Ichikawa, M.; Mizuno, I.; Yoshida, J.; Ide, N.; Ushijima, M.; Kodera, Y.; Hayama, M.; Ono, K. Pharmacokinetics of cycloalliin, an organosulfur compound found in garlic and onion, in rats. J. Agric. Food Chem., 2006, 54 (26), 9811-9819.
76. Tattelman, E. Health effects of garlic. Am. Fam. Physician., 2005, 72 (1),103-106.
77. Ho, B.E.; Shen, D.D.; McCune, J.S.; Bui, T.; Risler, L.; Yang, Z.; Ho, R.J. Effects of Garlic on Cytochromes P450 2C9- and 3A4- Mediated Drug Metabolism in Human Hepatocytes. Sci. Pharm., 2010, 78 (3),473-481.
78. Le Bon, A.M.; Vernevaut, M.F.; Guenot, L.; Kahane, R.; Auger, J.; Arnault, I.; Haffner, T.; Siess, M.H. Effects of garlic powders with varying alliin contents on hepatic drug metabolizing enzymes in rats. J. Agric. Food Chem., 2003, 51 (26),7617-7623.
79. Hajda, J.; Rentsch, K.M.; Gubler, C.; Steinert, H.; Stieger, B.; Fattinger, K. Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans. Eur. J. Pharm. Sci., 2010, 41 (5),729-735.
80. Berginc, K.; Kristl, A. The Mechanisms Responsible for Garlic - Drug Interactions and Their in vivo Relevance. Curr. Drug Metab., 2011. [Epub ahead of print]
81. Kelly, J.P.; Kaufman, D.W.; Kelley, K.; Rosenberg, L.; Anderson, T.E.; Mitchell, A.A. Recent trends in use of herbal and other natural products. Arch. Intern. Med., 2005, 165 (3),281-286.
82. Chen, Z.P.; Sun, J.; Chen, H.X.; Xiao, Y.Y.; Liu, D.; Chen, J.; Cai, H.; Cai, B.C. Comparative pharmacokinetics and bioavailability studies of quercetin, kaempferol and isorhamnetin after oral administration of Ginkgo biloba extracts, Ginkgo biloba extract phospholipid complexes and Ginkgo biloba extract solid dispersions in rats. Fitoterapia, 2010, 81 (8),1045-1052.
83. Deng, Y.; Bi H.C.; Zhao, L.Z.; He, F.; Liu, Y.Q.; Yu, J.J.; Ou, Z.M.; Ding, L.; Chen, X.; Huang, Z.Y.; Huang, M.; Zhou, S.F. Induction of cytochrome P450s by terpene trilactones and flavonoids of the Ginkgo biloba extract EGb 761 in rats. Xenobiotica., 2008, 38 (5),465-481.
84. Mukai, R.; Satsu, H.; Shimizu, M.; Ashida, H. Inhibition of Pglycoprotein enhances the suppressive effect of kaempferol on transformation of the aryl hydrocarbon receptor. Biosci. Biotechnol. Biochem., 2009, 73 (7),1635-1639.
85. Christensen, L.P. Ginsenosides chemistry, biosynthesis, analysis, and potential health effects. Adv. Food Nutr. Res., 2009, 55,1-99.
86. Wang, C.Z.; Mehendale, S.R.; Yuan, C.S. Commonly used antioxidant botanicals: active constituents and their potential role in cardiovascular illness. Am. J. Chin. Med., 2007, 35 (4),543-558.
87. Xie, J.T.; Zhou, Y.P.; Dey, L.; Attele, A.S.; Wu, J.A.; Gu, M.; Polonsky, K.S.; Yuan, C.S. Ginseng berry reduces blood glucose and body weight in db/db mice. Phytomedicine, 2002, 9 (3),254-258.
88. Visscher, C.M.; Ohrbach, R.; van Wijk, A.J.; Wilkosz M.; Naeije, M. The Tampa Scale for Kinesiophobia for Temporomandibular Disorders (TSK-TMD). Pain, 2010, 150 (3),492-500.
89. Feng, H.; Chen, W.; Zhu, C. Pharmacokinetics study of bioadhesive tablet of Panax notoginseng saponins. Int. Arch. Med., 2011, 4 (1),18.
90. Gu Y.; Wang G.J.; Sun J.G.; Jia Y.W.; Wang W.; Xu M.J.; Lv T.; Zheng Y.T.; Sai Y. Pharmacokinetic characterization of ginsenoside Rh2, an anticancer nutrient from ginseng, in rats and dogs. Food Chem. Toxicol., 2009, 47 (9),2257-2268.
91. Lau, W.S.; Chan, R.Y.; Guo, D.A.; Wong, M.S. Ginsenoside Rg1 exerts estrogen-like activities via ligand-independent activation of ERalpha pathway. J. Steroid. Biochem. Mol. Biol., 2008, 108 (1-2),64-71.
92. 3A and P-glycoprotein (P-gp) Activity in Healthy Participants. J. Clin. Pharmacol., 2011. [Epub ahead of print]
93. Liu, Y.; Zhang, J.W.; Li, W.; Ma, H.; Sun, J.; Deng, M.C.; Yang, L. Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicol. Sci., 2006, 91 (2),356-364.
94. Jin, J.; Shahi, S.; Kang, H.K.; van Veen, H.W.; Fan, T.P. Metabolites of ginsenosides as novel BCRP inhibitors. Biochem. Biophys. Res. Commun., 2006, 345 (4),1308-1314.
95. Choi, C.H.; Kang, G.; Min, Y.D. Reversal of P-glycoproteinmediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng. Planta Med., 2003, 69 (3),235-240.
96. Kim, S.W.; Kwon, H.Y.; Chi, D.W.; Shim, J.H.; Park, J.D.; Lee, Y.H.; Pyo, S.; Rhee, D.K. Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg(3). Biochem. Pharmacol., 2003, 65 (1),75-82.
97. Asl, M.N.; Hosseinzadeh, H. Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytother. Res., 2008, 22 (6),709-724.
98. Cao, J.; Chen, X.; Liang, J.; Yu, X.Q.; Xu, A.L.; Chan, E.; Wei, D.; Huang, M.; Wen, J.Y.; Yu, X.Y.; Li, X.T.; Sheu, F.S.; Zhou, S.F. Role of P-glycoprotein in the intestinal absorption of glabridin, an active flavonoid from the root of Glycyrrhiza glabra. Drug Metab. Dispos., 2007, 35 (4),539-553.
99. Park, S.Y.; Lim, S.S.; Kim, J.K.; Kang, I.J.; Kim, J.S.; Lee, C.; Kim, J.; Park, J.H. Hexane-ethanol extract of Glycyrrhiza uralensis containing licoricidin inhibits the metastatic capacity of DU145 human prostate cancer cells. Br. J. Nutr., 2010, 104 (9),1272-1282.
100. Tu, J.H.; He, Y.J.; Chen, Y.; Fan, L.; Zhang, W.; Tan, Z.R.; Huang, Y.F.; Guo, D.; Hu, D.L.; Wang, D.; Hong-Hao, Z. Effect of glycyrrhizin on the activity of CYP3A enzyme in humans. Eur. J. Clin. Pharmacol., 2010, 66 (8), 805-810.
101. Ngamukote, S.; Makynen, K.; Thilawech, T.; Adisakwattana, S. Cholesterol-lowering activity of the major polyphenols in grape seed. Molecules, 2011, 16 (6),5054-5061.
102. Walle, T. Bioavailability of resveratrol. Ann. N. Y. Acad. Sci., 2011, 1215,9-15.
103. Crowell, J.A.; Korytko, P.J.; Morrissey, R.L.; Booth, T.D.; Levine, B.S. Resveratrol-associated renal toxicity. Toxicol. Sci., 2004, 82 (2),614-619.
104. Chan, W.K.; Delucchi, A.B. Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci., 2000, 67 (25),3103-3112.
105. Chan, W.K.; Nguyen, L.T.; Miller, V.P.; Harris, R.Z. Mechanismbased inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine. Life Sci., 1998, 62 (10),PL135-142.
106. Piver, B.; Berthou, F.; Dreano, Y.; Lucas, D. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol. Lett., 2001, 125 (1-3),83-91.
107. Mikstacka, R.; Przybylska, D.; Rimando, A.M.; Baer-Dubowska, W. Inhibition of human recombinant cytochromes P450 CYP1A1 and CYP1B1 by trans-resveratrol methyl ethers. Mol. Nutr. Food Res., 2007, 51 (5),517-524.
108. Kim, J.H.; Chen, C.; Tony Kong, A.N. Resveratrol inhibits genistein- induced multi-drug resistance protein 2 (MRP2) expression in HepG2 cells. Arch. Biochem. Biophys., 2011, 512 (2),160-166.
109. National Toxicology Program. Toxicology and carcinogenesis studies of goldenseal root powder (Hydrastis Canadensis) in F344/N rats and B6C3F1 mice (feed studies). Natl. Toxicol. Program. Tech. Rep. Ser., 2010, 8(562),1-188.
110. Hua, W.; Ding, L.; Chen, Y.; Gong, B.; He, J.; Xu, G. Determination of berberine in human plasma by liquid chromatographyelectrospray ionization-mass spectrometry. J. Pharm. Biomed. Anal., 2007, 44 (4),931-937.
111. Dunnick, J.K.; Singh, B.; Nyska, A.; Peckham, J.; Kissling, G.E.; Sanders, J.M. Investigating the potential for toxicity from longterm use of the herbal products, goldenseal and milk thistle. Toxicol. Pathol., 2011, 39 (2),398-409.
112. Sandhu, R.S.; Prescilla, R.P.; Simonelli, T.M.; Edwards, D.J. Influence of goldenseal root on the pharmacokinetics of indinavir. J. Clin. Pharmacol., 2003, 43 (11),1283-1288.
113. Gurley, B.J.; Swain, A.; Hubbard, M.A.; Williams, D.K.; Barone, G.; Hartsfield, F.; Tong, Y.; Carrier, D.J.; Cheboyina, S.; Battu, S.K. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. Mol. Nutr. Food Res., 2008, 52 (7),755-763.
114. Gurley, B.J.; Swain, A.; Barone, G.W.; Williams, D.K.; Breen, P.; Yates, C.R.; Stuart, L.B.; Hubbard, M.A.; Tong, Y.; Cheboyina, S. Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans. Drug Metab. Dispos., 2007, 35 (2),240-245.
115. Sarris, J.; La Porte, E.; Schweitzer, I. Kava: a comprehensive review of efficacy, safety, and psychopharmacology. Aust. N. Z. J. Psychiatry., 2011, 45 (1),27-35.
116. Mathews, J.M.; Etheridge, A.S.; Valentine, J.L.; Black, S.R.; Coleman, D.P.; Patel, P.; So, J.; Burka, L.T. Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro. Drug Metab. Dispos., 2005, 33 (10),1555-1563.
117. Teschke, R.; Sarris J.; Schweitzer I. Kava hepatotoxicity in traditional and modern use: The presumed Pacific kava paradox hypothesis revisited. Br. J. Clin. Pharmacol., 2012, 73(2), 170-174.
118. Mathews, J.M.; Etheridge, A.S.; Black, S.R. Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drug Metab. Dispos., 2002, 30 (11),1153-1157.
119. Chen, W.; Zhang, Y.; Liu, J.P. Chinese herbal medicine for diabetic peripheral neuropathy. Cochrane. Database. Syst. Rev., 2011, 6,CD007796.
120. Lv, G.; Lou, Z.; Chen, S.; Gu, H.; Shan, L. Pharmacokinetics and tissue distribution of 2,3,5,4'-tetrahydroxystilbene-2-O-beta-dglucoside from traditional Chinese medicine Polygonum multiflorum following oral administration to rats. J. Ethnopharmacol., 2011, 137(1): 449-456.
121. Wen, Z.; Dumas, T.E.; Schrieber, S.J.; Hawke, R.L.; Fried, M.W.; Smith, P.C. Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab. Dispos., 2008, 36 (1),65-72.
122. Loguercio, C.; Festi, D. Silybin and the liver: from basic research to clinical practice. World J. Gastroenterol., 2011, 17 (18),2288-2301.
123. Sridar, C.; Goosen, T.C.; Kent, U.M.; Williams, J.A.; Hollenberg, P.F. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab. Dispos., 2004, 32 (6),587-594.
124. Lee, C.K.; Choi, J.S. Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats. Pharmacology, 2010, 85 (6),350-356.
125. Dzubak, P.; Hajduch, M.; Gazak, R.; Svobodova, A.; Psotova, J.; Walterova, D.; Sedmera P.; Kren V. New derivatives of silybin and 2,3-dehydrosilybin and their cytotoxic and P-glycoprotein modulatory activity. Bioorg. Med. Chem., 2006, 14 (11),3793-3810.
126. Wu, S.H.; Wu, D.G.; Chen, Y.W. Chemical constituents and bioactivities of plants from the genus Paeonia. Chem. Biodivers., 2010, 7 (1),90-104.
127. Takeda, S.; Isono, T.; Wakui, Y.; Matsuzaki, Y.; Sasaki, H.; Amagaya, S.; Maruno, M. Absorption and excretion of paeoniflorin in rats. J. Pharm. Pharmacol., 1995, 47 (12A),1036-1040.
128. He, D.Y.; Dai, S.M. Anti-inflammatory and immunomodulatory effects of paeonia lactiflora pall., a traditional chinese herbal medicine. Front. Pharmacol., 2011, 2,10.
129. Hu S.; Shen, G.; Zhao, W.; Wang, F.; Jiang, X.; Huang, D. Paeonol, the main active principles of Paeonia moutan, ameliorates alcoholic steatohepatitis in mice. J. Ethnopharmacol., 2010, 128 (1),100-106.
130. Liu, Z.Q.; Jiang, Z.H.; Liu, L.; Hu, M. Mechanisms responsible for poor oral bioavailability of paeoniflorin: Role of intestinal disposition and interactions with sinomenine. Pharm. Res., 2006, 23 (12),2768-2780.
131. Chan, K.; Liu, Z.Q.; Jiang, Z.H.; Zhou, H.; Wong, Y.F.; Xu, H.X.; Liu, L. The effects of sinomenine on intestinal absorption of paeoniflorin by the everted rat gut sac model. J. Ethnopharmacol., 2006, 103 (3),425-432.
132. Hoyland, H.K. Use of Saint Johns wort against mild depression. Tidsskr. Nor. Laegeforen., 2011, 131 (8),837-839.
133. Kerb, R.; Brockmoller, J.; Staffeldt, B.; Ploch, M.; Roots, I. Singledose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob. Agents Chemother., 1996, 40 (9),2087-2093.
134. Ghazanfarpour, M.; Kaviani, M.; Asadi, N.; Ghaffarpasand, F.; Ziyadlou, S.; Tabatabaee, H.R.; Dehghankhalili, M. Hypericum perforatum for the treatment of premenstrual syndrome. Int. J. Gynaecol. Obstet., 2011, 113 (1),84-85.
135. Lau, W.C.; Welch, T.D.; Shields, T.; Rubenfire, M.; Tantry, U.S.; Gurbel, P.A. The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. J. Cardiovasc. Pharmacol., 2011, 57 (1),86-93.
136. Hokkanen, J.; Tolonen, A.; Mattila, S.; Turpeinen, M. Metabolism of hyperforin, the active constituent of St. John's wort, in human liver microsomes. Eur. J. Pharm. Sci., 2011, 42 (3),273-284.
137. Ott, M.; Huls, M.; Cornelius, M.G.; Fricker, G. St. John's Wort constituents modulate P-glycoprotein transport activity at the blood-brain barrier. Pharm. Res., 2010, 27 (5),811-822.
138. Li, B.; Zhou, X.X.; Liang, M.X. Research and prospect on reducing the toxicity and enhancing the efficacy of Tipterygium wilfordii by combined use of Chinese medicine. Zhong. guo. Zhong. Xi. Yi. Jie. He. Za. Zhi., 2006, 26 (11),1045-1048.
139. Wong, K.F.; Yi Y.; Luk, J.M. Tripterygium wilfordii bioactive compounds as anti-cancer and anti-inflammatory agents. Clin. Exp. Pharmacol. Physiol., 2012, 39(3), 311-320.
140. Shao, F.; Wang, G.; Xie, H.; Zhu, X.; Sun, J.; A J. Pharmacokinetic study of triptolide, a constituent of immunosuppressive chinese herb medicine, in rats. Biol. Pharm. Bull., 2007, 30 (4),702-707.
141. Ni, B.; Jiang, Z.; Huang, X.; Xu, F.; Zhang, R.; Zhang, Z.; Tian, Y.; Wang, T.; Zhu, T.; Liu, J.; Zhang, L. Male reproductive toxicity and toxicokinetics of triptolide in rats. Arzneimittelforschung., 2008, 58 (12),673-680.
142. Liu, L.; Jiang, Z.; Liu, J.; Huang, X.; Wang, T.; Zhang, Y.; Zhou, Z.; Guo, J.; Yang L.; Chen Y.; Zhang L. Sex differences in subacute toxicity and hepatic microsomal metabolism of triptolide in rats. Toxicology, 2010, 271 (1-2),57-63.
143. Li, W.; Liu, Y.; He, Y.Q.; Zhang, J.W.; Gao, Y.; Ge, G.B.; Liu, H.X.; Huo, H.; Liu, H.T.; Wang, L.M.; Sun, J.; Wang, Q.; Yang, L. Characterization of triptolide hydroxylation by cytochrome P450 in human and rat liver microsomes. Xenobiotica, 2008, 38 (12),1551-1565.
144. Chen, Y.W.; Lin, G.J.; Chuang, Y.P.; Chia, W.T.; Hueng, D.Y.; Lin, C.K.; Nieh, S.; Sytwu, H.K. Triptolide circumvents drugresistant effect and enhances 5-fluorouracil antitumor effect on KB cells. Anticancer Drugs, 2010, 21 (5),502-513.
145. Taavoni, S.; Ekbatani, N.; Kashaniyan, M.; Haghani, H. Effect of valerian on sleep quality in postmenopausal women: a randomized placebo-controlled clinical trial. Menopause, 2011, 18(9),951-955
146. Barton, D.L.; Atherton, P.J.; Bauer, B.A.; Moore, D.F., Jr.; Mattar, B.I.; Lavasseur, B.I.; Rowland, K.M., Jr.; Zon, R.T.; Lelindqwister, N.A.; Nagargoje, G.G.; Morgenthaler, T.I.; Sloan, J.A.; Loprinzi, C.L. The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5). J. Suppor.t Oncol., 2011, 9 (1),24-31.
147. Anderson, G.D.; Elmer, G.W.; Kantor, E.D.; Templeton, I.E.; Vitiello, M.V. Pharmacokinetics of valerenic acid after administration of valerian in healthy subjects. Phytother. Res., 2005, 19 (9),801-803.
148. Maier-Salamon, A.; Trauner, G.; Hiltscher, R.; Reznicek, G.; Kopp, B.; Thalhammer, T.; Jager, W. Hepatic metabolism and biliary excretion of valerenic acid in isolated perfused rat livers: role of Mrp2 (Abcc2). J. Pharm. Sci., 2009, 98 (10),3839-3849.
149. MacGregor, F.B.; Abernethy, V.E.; Dahabra, S.; Cobden, I.; Hayes, P.C. Hepatotoxicity of herbal remedies. BMJ., 1989, 299 (6708),1156-1157.
150. Shaw, D.; Leon, C.; Kolev, S.; Murray, V. Traditional remedies and food supplements. A 5-year toxicological study (1991-1995). Drug Saf., 1997, 17 (5),342-356.
151. Lefebvre, T.; Foster, B.C.; Drouin, C.E.; Krantis, A.; Livesey, J.F.; Jordan, S.A. In vitro activity of commercial valerian root extracts against human cytochrome P450 3A4. J. Pharm. Pharm. Sci., 2004, 7 (2),265-273.
152. Alkharfy, K.M.; Frye, R.F. Effect of valerian, valerian/hops extracts, and valerenic acid on glucuronidation in vitro. Xenobiotica, 2007, 37 (2),113-123.
153. Liu, H.; Yang, J.; Du, F.; Gao, X.; Ma, X.; Huang, Y.; Xu, F.; Niu, W.; Wang, F.; Mao, Y.; Sun, Y.; Lu, T.; Liu, C.; Zhang, B.; Li, C. Absorption and disposition of ginsenosides after oral administration of Panax notoginseng extract to rats. Drug Metab. Dispos., 2009, 37 (12),2290-2298.
154. Hsu, C.H.; Cheng, A.L. Clinical studies with curcumin. Adv. Exp. Med. Biol., 2007, 595,471-480.
155. Sharma, R.A.; Steward, W.P.; Gescher, A.J. Pharmacokinetics and pharmacodynamics of curcumin. Adv. Exp. Med. Biol., 2007, 595,453-470.
156. Vitaglione, P.; Sforza, S.; Galaverna, G.; Ghidini, C.; Caporaso, N.; Vescovi, P.P.; Fogliano, V.; Marchelli, R. Bioavailability of transresveratrol from red wine in humans. Mol. Nutr. Food Res., 2005, 49 (5),495-504.
157. Pan, M.H.; Huang, T.M.; Lin, J.K. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab. Dispos., 1999, 27 (4),486-494.
158. Wang, Y.; Hao, H.; Wang, G.; Tu, P.; Jiang, Y.; Liang, Y.; Dai, L.; Yang, H.; Lai, L.; Zheng, C.; Wang, Q.; Cui, N.; Liu, Y. An approach to identifying sequential metabolites of a typical phenylethanoid glycoside, echinacoside, based on liquid chromatographyion trap-time of flight mass spectrometry analysis. Talanta., 2009, 80 (2),572-580.
159. Liu, Y.; Hao, H.; Xie, H.; Lv, H.; Liu, C.; Wang, G. Oxidative demethylenation and subsequent glucuronidation are the major metabolic pathways of berberine in rats. J. Pharm. Sci., 2009, 98 (11),4391-4401.
160. Barve, A.; Chen, C.; Hebbar, V.; Desiderio, J.; Saw, C.L.; Kong, A.N. Metabolism, oral bioavailability and pharmacokinetics of chemopreventive kaempferol in rats. Biopharm. Drug Dispos., 2009, 30 (7),356-365.
161. Shia, C.S.; Tsai, S.Y.; Lin, J.C.; Li, M.L.; Ko, M.H.; Chao, P.D.; Huang, Y.C.; Hou, Y.C. Steady-state pharmacokinetics and tissue distribution of anthraquinones of Rhei Rhizoma in rats. J. Ethnopharmacol., 2011, 137(3),1388-1394.
162. Hao, H.; Wang, G.; Cui, N.; Li, J.; Xie, L.; Ding, Z. Pharmacokinetics, absorption and tissue distribution of tanshinone IIA solid dispersion. Planta Med., 2006, 72 (14),1311-1317.
163. Zhang, W.D.; Zhang, C.; Liu, R.H.; Li, H.L.; Zhang, J.T.; Mao, C.; Moran, S.; Chen C.L. Preclinical pharmacokinetics and tissue distribution of a natural cardioprotective agent astragaloside IV in rats and dogs. Life Sci., 2006, 79 (8),808-815.
164. Chen, S.M.; Fan, M.Y.; Tseng, C.C.; Ho, Y.; Hsu, K.Y. Pharmacokinetics and nephrotoxicity of aristolochic acid in rabbits. Toxicon., 2007, 50 (2),180-188.
165. Yang, H.Y.; Zheng, X.H.; Du, Y.; Chen, Z.; Zhu, D.Y.; Lou, Y.J. Kinetics of aristolochic acid I after oral administration of Radix Aristolochiae or Guanxinsuhe preparation in canines. J. Ethnopharmacol., 2011, 135 (2),569-574.
166. Liu, C.X.; Xiao, P.G. Recent advances on ginseng research in China. J. Ethnopharmacol., 1992, 36 (1),27-38.
167. Kiefer D.; Pantuso, T. Panax ginseng. Am. Fam. Physician., 2003, 68 (8),1539-1542.
168. Lu, J.M.; Yao, Q.; Chen, C. Ginseng compounds: an update on their molecular mechanisms and medical applications. Curr. Vasc. Pharmacol., 2009, 7 (3),293-302.
169. Attele A.S.; Wu, J.A.; Yuan, C.S. Ginseng pharmacology: multiple constituents and multiple actions. Biochem. Pharmacol., 1999, 58 (11),1685-1693.
170. Tang, B.; Qu, Y.; Wang, D.; Mu, D. Targeting hypoxia inducible factor-1alpha: a novel mechanism of ginsenoside Rg1 for brain repair after hypoxia/ischemia brain damage. CNS. Neurol. Disord. Drug Targets, 2011, 10 (2),235-238.
171. Lee, S.D.; Lo, M.J. Ginsenoside Rb1 promotes PC12 cell cycle kinetics through an adenylate cyclase-dependent protein kinase A pathway. Nutr. Res., 2010, 30 (9),660-666.
172. Liang, W.; Ge, S.; Yang, L.; Yang, M.; Ye, Z.; Yan, M.; Du, J.; Luo, Z. Ginsenosides Rb1 and Rg1 promote proliferation and expression of neurotrophic factors in primary Schwann cell cultures. Brain Res., 2010, 1357,19-25.
173. Xu, H.; Jiang, H.; Wang, J.; Xie, J. Rg1 protects iron-induced neurotoxicity through antioxidant and iron regulatory proteins in 6- OHDA-treated MES23.5 cells. J. Cell Biochem., 2010, 111 (6),1537-1545.
174. Kim, T.H.; Lee, S.M. The effects of ginseng total saponin, panaxadiol and panaxatriol on ischemia/reperfusion injury in isolated rat heart. Food Chem. Toxicol., 2010, 48 (6),1516-1520.
175. Yi, X.Q.; Li, T.; Wang, J.R.; Wong, V.K.; Luo, P.; Wong, I.Y.; Jiang, Z.H.; Liu, L.; Zhou H. Total ginsenosides increase coronary perfusion flow in isolated rat hearts through activation of PI3K/Akt-eNOS signaling. Phytomedicine, 2010, 17 (13),1006-1015.
176. Wang, T.; Yu, X.F.; Qu, S.C.; Xu, H.L.; Sui D.Y. Ginsenoside Rb3 inhibits angiotensin II-induced vascular smooth muscle cells proliferation. Basic. Clin. Pharmacol. Toxicol., 2010, 107 (2),685-689.
177. Xu, Z.; Lan, T.; Wu, W.; Wu, Y. The effects of ginsenoside Rb1 on endothelial damage and ghrelin expression induced by hyperhomocysteine. J. Vasc. Surg., 2011, 53 (1),156-164.
178. Zhang, S.D.; Yin, Y.X.; Wei, Q. Immunopotentiation on murine spleen lymphocytes induced by polysaccharide fraction of Panax ginseng via upregulating calcineurin activity. APMIS., 2010, 118 (4),288-296.
179. Liu, R.; Zhang, J.; Liu, W.; Kimura, Y.; Zheng, Y. Anti-Obesity effects of protopanaxdiol types of Ginsenosides isolated from the leaves of American ginseng (Panax quinquefolius L.) in mice fed with a high-fat diet. Fitoterapia, 2010, 81 (8),1079-1087.
180. Li, B.; Zhao, J.; Wang, C.Z.; Searle, J.; He, T.C.; Yuan, C.S.; Du, W. Ginsenoside Rh2 induces apoptosis and paraptosis-like cell death in colorectal cancer cells through activation of p53. Cancer Lett., 2011, 301 (2),185-192.
181. Chen, S.E.; Sawchuk, R.J.; Staba, E.J. American ginseng. III. Pharmacokinetics of ginsenosides in the rabbit. Eur. J. Drug Metab. Pharmacokinet, 1980, 5 (3),161-168.
182. Takino, Y.; Odani, T.; Tanizawa, H.; Hayashi, T. Studies on the absorption, distribution, excretion and metabolism of ginseng saponins. I. Quantitative analysis of ginsenoside Rg1 in rats. Chem. Pharm. Bull. (Tokyo), 1982, 30 (6),2196-2201.
183. Odan,i T.; Tanizawa, H.; Takino, Y. Studies on the absorption, distribution, excretion and metabolism of ginseng saponins. II. The absorption, distribution and excretion of ginsenoside Rg1 in the rat. Chem. Pharm. Bull. (Tokyo), 1983, 31 (1),292-298.
184. Odani, T.; Tanizawa, H.; Takino, Y. Studies on the absorption, distribution, excretion and metabolism of ginseng saponins. III. The absorption, distribution and excretion of ginsenoside Rb1 in the rat. Chem. Pharm. Bull. (Tokyo), 1983, 31 (3),1059-1066.
185. Xu, Q.F.; Fang, X.L.; Chen, D.F. Pharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats. J. Ethnopharmacol., 2003, 84 (2-3), 187-192.
186. Lai, L.; Hao, H.; Liu, Y.; Zheng, C.; Wang, Q.; Wang, G.; Chen, X. Characterization of pharmacokinetic profiles and metabolic pathways of 20(S)-ginsenoside Rh1 in vivo and in vitro. Planta Med., 2009, 75 (8),797-802.
187. Lee, P.S.; Song, T.W.; Sung, J.H.; Moon, D.C.; Song, S.; Chung, Y.B. Pharmacokinetic characteristics and hepatic distribution of IH-901, a novel intestinal metabolite of ginseng saponin, in rats. Planta Med., 2006, 72 (3),204-210.
188. Xie, H.T.; Wang, G.J.; Sun, J.G.; Tucker, I.; Zhao, X.C.; Xie, Y.Y.; Li, H.; Jiang, X.L.; Wang, R.; Xu, M.J.; Wang, W. High performance liquid chromatographic-mass spectrometric determination of ginsenoside Rg3 and its metabolites in rat plasma using solid-phase extraction for pharmacokinetic studies. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 2005, 818 (2),167-173.
189. Paek, I.B.; Moon, Y.; Kim, J.; Ji, H.Y.; Kim, S.A.; Sohn, D.H.; Kim, J.B.; Lee, H.S. Pharmacokinetics of a ginseng saponin metabolite compound K in rats. Biopharm. Drug Dispos., 2006, 27 (1),39-45.
190. Xie, H.T.; Wang G.J.; Lv, H.; Sun, R.W.; Jiang, X.L.; Li, H.; Wang, W.; Huang, C.R.; Xu, M.J. Development of a HPLC-MS assay for ginsenoside Rh2, a new anti-tumor substance from natural product and its pharacokinetic study in dogs. Eur. J. Drug Metab. Pharmacokinet, 2005, 30 (1-2),63-67.
191. Wang, W.; Wang, G.J.; Xie, H.T.; Sun, J.G.; Zhao, S.; Jiang, X.L.; Li, H.; Lv, H.; Xu, M.J.; Wang, R. Determination of ginsenoside Rd in dog plasma by liquid chromatography-mass spectrometry after solid-phase extraction and its application in dog pharmacokinetics studies. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 2007, 852 (1-2),8-14.
192. Joo, K.M.; Lee, J.H.; Jeon, H.Y.; Park, C.W.; Hong, D.K.; Jeong, H.J.; Lee, S.J.; Lee S.Y.; Lim, K.M. Pharmacokinetic study of ginsenoside Re with pure ginsenoside Re and ginseng berry extracts in mouse using ultra performance liquid chromatography/mass spectrometric method. J. Pharm. Biomed. Anal., 2010, 51 (1),278-283.
193. Hao, M.; Wang, W.; Zhao, Y.; Zhang, R.; Wang, H. Pharmacokinetics and tissue distribution of 25-hydroxyprotopanaxadiol, an anti-cancer compound isolated from Panax ginseng, in athymic mice bearing xenografts of human pancreatic tumors. Eur. J. Drug Metab. Pharmacokinet., 2011, 35 (3-4),109-113.
194. Han, M.; Sha, X.; Wu, Y.; Fang, X. Oral absorption of ginsenoside Rb1 using in vitro and in vivo models. Planta Med., 2006, 72 (5),398-404.
195. Gu, Y.; Wang, G.J.; Wu, X.L.; Zheng, Y.T.; Zhang, J.W.; Ai, H.; Sun, J.G.; Jia, Y.W. Intestinal absorption mechanisms of ginsenoside Rh2: stereoselectivity and involvement of ABC transporters. Xenobiotica, 2010, 40 (9), 602-612.
196. Qi, L.W.; Wang, C.Z.; Du, G.J.; Zhang, Z.Y.; Calway, T.; Yuan, C.S. Metabolism of Ginseng and its Interactions with Drugs. Curr. Drug Metab., 2011, 12(9),818-822.
197. Tawab, M.A.; Bahr U.; Karas M.; Wurglics M.; Schubert-Zsilavecz M. Degradation of ginsenosides in humans after oral administration. Drug Metab. Dispos., 2003, 31 (8),1065-1071.
198. Hasegawa H.; Lee K.S.; Nagaoka T.; Tezuka Y.; Uchiyama M.; Kadota S.; Saiki I. Pharmacokinetics of ginsenoside deglycosylated by intestinal bacteria and its transformation to biologically active fatty acid esters. Biol. Pharm. Bull., 2000, 23 (3),298-304.
199. Li L.; Chen X.; Li D.; Zhong D. Identification of 20(S)- protopanaxadiol metabolites in human liver microsomes and human hepatocytes. Drug Metab. Dispos., 2011, 39 (3),472-483.
200. Qian T.; Cai Z.; Wong R.N.; Mak N.K.; Jiang Z.H. In vivo rat metabolism and pharmacokinetic studies of ginsenoside Rg3. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 2005, 816 (1-2),223-232.
201. Wang W.; Liao Q.P.; Quan L.H.; Liu C.Y.; Chang Q.; Liu X.M.; Liao Y.H. The effect of Acorus gramineus on the bioavailabilities and brain concentrations of ginsenosides Rg1, Re and Rb1 after oral administration of Kai-Xin-San preparations in rats. J. Ethnopharmacol., 2010, 131 (2),313-320.
202. Kang A.; Hao H.; Zheng X.; Liang Y.; Xie Y.; Xie T.; Dai C.; Zhao Q.; Wu X.; Xie L.; Wang G. Peripheral anti-inflammatory effects explain the ginsenosides paradox between poor brain distribution and anti-depression efficacy. J. Neuroinflammation, 2011, 8 (1),100.
203. Feng L.; Wang L.; Hu C.; Jiang X. Pharmacokinetics, tissue distribution, metabolism, and excretion of ginsenoside Rg1 in rats. Arch. Pharm. Res., 2010, 33 (12),1975-1984.
204. Cromwell B.T. Experiments on the origin and function of berberine in Berberis Darwinii. Biochem. J., 1933, 27 (3),860-872.
205. Sharma R.; Joshi C.K.; Goyal R.K. Berberine tannate in acute diarrhoea. Indian. Pediatr., 1970, 7 (9),496-501.
206. Liu, Q.; Jiang, H.; Liu, Z.; Wang, Y.; Zhao, M.; Hao, C.; Feng, S.; Guo, H.; Xu, B.; Yang, Q.; Gong, Y.; Shao, C. Berberine Radiosensitizes Human Esophageal Cancer Cells by Downregulating Homologous Recombination Repair Protein RAD51. PLoS One, 2011, 6 (8),e23427.
207. Yan, K.; Zhang, C.; Feng, J.; Hou, L.; Yan, L.; Zhou, Z.; Liu, Z.; Liu, C.; Fan, Y.; Zheng, B.; Xu, Z. Induction of G1 cell cycle arrest and apoptosis by berberine in bladder cancer cells. Eur. J. Pharmacol., 2011, 661 (1-3),1-7.
208. Sun, Y.; Xun, K.; Wang, Y.; Chen, X. A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs. Anticancer Drugs, 2009, 20 (9),757-769.
209. Imanshahidi, M.; Hosseinzadeh, H. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother. Res., 2008, 22 (8),999-1012.
210. Boberek, J.M.; Stach, J.; Good, L. Genetic evidence for inhibition of bacterial division protein FtsZ by berberine. PLoS One, 2010, 5 (10),e13745.
211. Zhang, Q.; Piao, X.L.; Piao, X.S.; Lu, T.; Wang, D.; Kim, S.W. Preventive effect of Coptis chinensis and berberine on intestinal injury in rats challenged with lipopolysaccharides. Food Chem. Toxicol., 2011, 49 (1),61-69.
212. Gu, L.; Li, N.; Li, Q.; Zhang, Q.; Wang, C.; Zhu, W.; Li, J. The effect of berberine in vitro on tight junctions in human Caco-2 intestinal epithelial cells. Fitoterapia, 2009, 80 (4),241-248.
213. Gu, L.; Li, N.; Gong, J.; Li, Q.; Zhu, W.; Li, J. Berberine ameliorates intestinal epithelial tight-junction damage and down-regulates myosin light chain kinase pathways in a mouse model of endotoxinemia. J. Infect. Dis., 2011, 203 (11),1602-1612.
214. Wang, Y.; Jia, X.; Ghanam, K.; Beaurepaire, C.; Zidichouski, J.; Miller, L. Berberine and plant stanols synergistically inhibit cholesterol absorption in hamsters. Atherosclerosis, 2010, 209 (1),111-117.
215. Guan, S.; Wang, B.; Li, W.; Guan, J.; Fang, X. Effects of berberine on expression of LOX-1 and SR-BI in human macrophage-derived foam cells induced by ox-LDL. Am. J. Chin. Med., 2010, 38 (6),1161-1169.
216. Li, K.; Yao, W.; Zheng, X.; Liao, K. Berberine promotes the development of atherosclerosis and foam cell formation by inducing scavenger receptor A expression in macrophage. Cell Res., 2009, 19 (8),1006-1017.
217. Huang, Z.; Wang, L.; Meng, S.; Wang, Y.; Chen, T.; Wang, C. Berberine reduces both MMP-9 and EMMPRIN expression through prevention of p38 pathway activation in PMA-induced macrophages. Int. J. Cardiol., 2011, 146 (2),153-158.
218. Liu, L.; Yu, Y.L.; Yang, J.S.; Li, Y.; Liu, Y.W.; Liang Y.; Liu, X.D.; Xie, L.; Wang, G.J. Berberine suppresses intestinal disaccharidases with beneficial metabolic effects in diabetic states, evidences from in vivo and in vitro study. Naunyn. Schmiedebergs. Arch. Pharmacol., 2010, 381 (4),371-381.
219. Pan G.Y.; Huang Z.J.; Wang G.J.; Fawcett J.P.; Liu X.D.; Zhao X.C.; Sun J.G.; Xie Y.Y. The antihyperglycaemic activity of berberine arises from a decrease of glucose absorption. Planta Med., 2003, 69 (7),632-636.
220. Yu Y.; Liu L.; Wang X.; Liu X.; Xie L.; Wang G. Modulation of glucagon-like peptide-1 release by berberine: in vivo and in vitro studies. Biochem. Pharmacol., 2010, 79 (7),1000-1006.
221. Zhang H.; Wei J.; Xue R.; Wu J.D.; Zhao W.; Wang Z.Z.; Wang S.K.; Zhou Z.X.; Song D.Q.; Wang Y.M.; Pan H.N.; Kong W.J.; Jiang J.D. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism, 2010, 59 (2),285-292.
222. Li B.; Zhang M.; Bao L. Study on the pharmacokinetics of berberine after oral administration in human being. J. Haerbin. Med. Univ., 1995, 29 (5),382-385.
223. Lu T.; Liang Y.; Song J.; Xie L.; Wang G.J.; Liu X.D. Simultaneous determination of berberine and palmatine in rat plasma by HPLC-ESI-MS after oral administration of traditional Chinese medicinal preparation Huang-Lian-Jie-Du decoction and the pharmacokinetic application of the method. J. Pharm. Biomed. Anal., 2006, 40 (5),1218-1224.
224. Xiong C.; Shi X.; Dai Z.; Fang D. Pharmacokinetic study of 3Hberberine in rabbits and mouse. Chin. Pharmacol. Bull., 1989, 5 (5),293-296.
225. Chen, W.; Miao, Y.Q.; Fan, D.J.; Yang, S.S.; Lin, X.; Meng, L.K.; Tang, X. Bioavailability Study of Berberine and the Enhancing Effects of TPGS on Intestinal Absorption in Rats. AAPS. Pharm- SciTech., 2011, 12 (2),705-711.
226. Battu, S.K.; Repka, M.A.; Maddineni, S.; Chittiboyina, A.G.; Avery, M.A.; Majumdar, S. Physicochemical characterization of berberine chloride: a perspective in the development of a solution dosage form for oral delivery. AAPS PharmSciTech., 2010, 11 (3),1466-1475.
227. Zhang, X.; Qiu, F.; Jiang, J.; Gao, C.; Tan, Y. Intestinal absorption mechanisms of berberine, palmatine, jateorhizine, and coptisine: involvement of P-glycoprotein. Xenobiotica, 2011, 41 (4),290-296.
228. Pan, G.Y.; Wang, G.J.; Liu, X.D.; Fawcett, J.P.; Xie, Y.Y. The involvement of P-glycoprotein in berberine absorption. Pharmacol. Toxicol., 2002, 91 (4),193-197.
229. Maeng, H.J.; Yoo, H.J.; Kim, I.W.; Song, I.S.; Chung, S.J.; Shim, C.K. P-glycoprotein-mediated transport of berberine across Caco-2 cell monolayers. J. Pharm. Sci., 2002, 91 (12),2614-2621.
230. Chen, Y.; Wang, X.; Sun, H.; Xing, D.; Hu, J.; Wai, Z.; Du, L. Characterization of the transportation of berberine in Coptidis rhizoma extract through rat primary cultured cortical neurons. Biomed. Chromatogr., 2008, 22 (1),28-33.
231. Chen, C.M.; Chang, H.C. Determination of berberine in plasma, urine and bile by high-performance liquid chromatography. J. Chromatogr. B. Biomed. Appl., 1995, 665 (1),117-123.
232. Tsai, P.L.; Tsai, T.H. Hepatobiliary excretion of berberine. Drug Metab. Dispos., 2004, 32 (4),405-412.
233. Li, Y.; Ren, G.; Wang, Y.X.; Kong, W.J.; Yang, P.; Wang, Y.M.; Li, Y.H.; Yi, H.; Li, Z.R.; Song, D.Q.; Jiang, J.D. Bioactivities of berberine metabolites after transformation through CYP450 isoenzymes. J. Transl. Med., 2011, 9,62.
234. Liu, Y.T.; Hao, H.P.; Xie, H.G.; Lai, L.; Wang, Q.; Liu, C.X.; Wang, G.J. Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats. Drug Metab. Dispos., 2010, 38 (10),1779-1784.
235. Guo, Y.; Chen, Y.; Tan, Z.R.; Klaassen, C.D.; Zhou, H.H. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur. J. Clin. Pharmacol., 2012, 68(2), 213-217.
236. Zhou, C.; Li, X.C.; Fang, W.H.; Yang, X.L.; Hu, L.L.; Zhou, S.; Zhou, J.F. Inhibition of CYP450 1A and 3A by berberine in crucian carp Carassius auratus gibelio. Comp. Biochem. Physiol. C. Toxicol. Pharmacol., 2011, 154(4), 360-366.
237. Zhao, Y.; Hellum B.H.; Liang, A.; Nilsen, O.G. The In vitro Inhibition of Human CYP1A2, CYP2D6 and CYP3A4 by Tetrahydropalmatine, Neferine and Berberine. Phytother. Res., 2012, 26(2), 277-283.
238. Chatuphonprasert, W.; Sangkawat, T.; Nemoto, N.; Jarukamjorn, K. Suppression of beta-naphthoflavone induced CYP1A expression and lipid-peroxidation by berberine. Fitoterapia, 2011, 82 (6),889-895.
239. Liu, L.Z.; Cheung, S.C.; Lan, L.L.; Ho, S.K.; Xu, H.X.; Chan, J.C.; Tong, P.C. Berberine modulates insulin signaling transduction in insulin-resistant cells. Mol. Cell Endocrino., 2010, 317 (1-2),148-153.
240. Zhou, J.; Zhou, S.; Tang, J.; Zhang, K.; Guang, L.; Huang, Y.; Xu, Y.; Ying, Y.; Zhang, L.; Li, D. Protective effect of berberine on beta cells in streptozotocin- and high-carbohydrate/high-fat dietinduced diabetic rats. Eur. J. Pharmacol.,2009, 606 (1-3),262-268.
241. Singh, J.; Kakkar, P. Antihyperglycemic and antioxidant effect of Berberis aristata root extract and its role in regulating carbohydrate metabolism in diabetic rats. J. Ethnopharmacol., 2009, 123 (1),22-26.
242. Cheng, T.O. Danshen: a popular chinese cardiac herbal drug. J. Am. Coll. Cardiol., 2006, 47 (7),1498.
243. Cheng, T.O. Danshen: what every cardiologist should know about this Chinese herbal drug. Int. J. Cardiol., 2006, 110 (3),411-412.
244. Zhou, L.; Zuo, Z.; Chow, M.S. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J. Clin. Pharmacol., 2005, 45 (12),1345-1359.
245. Cheng, T.O. Cardiovascular effects of Danshen. Int. J. Cardiol., 2007, 121 (1),9-22.
246. Wang, X.; Morris-Natschke, S.L.; Lee, K.H. New developments in the chemistry and biology of the bioactive constituents of Tanshen. Med. Res. Rev., 2007, 27 (1),133-148.
247. Pan, T.L.; Hung, Y.C.; Wang, P.W.; Chen, S.T.; Hsu, T.K.; Sintupisut, N.; Cheng, C.S.; Lyu, P.C. Functional proteomic and structural insights into molecular targets related to the growth inhibitory effect of tanshinone IIA on HeLa cells. Proteomics, 2010, 10 (5),914-929.
248. Park, I.J.; Kim, M.J.; Park, O.J.; Park, M.G.; Choe, W.; Kang, I.; Kim, S.S.; Ha, J. Cryptotanshinone sensitizes DU145 prostate cancer cells to Fas(APO1/CD95)-mediated apoptosis through Bcl-2 and MAPK regulation. Cancer Lett., 2010, 298 (1),88-98.
249. Gong, Y.; Li, Y.; Lu, Y.; Li, L.; Abdolmaleky, H.; Blackburn, G.L.; Zhou, J.R. Bioactive tanshinones in Salvia miltiorrhiza inhibit the growth of prostate cancer cells in vitro and in mice. Int. J. Cancer, 2011, 129 (5),1042-1052.
250. Liu, X.D.; Fan, R.F.; Zhang, Y.; Yang, H.Z.; Fang, Z.G.; Guan, W.B.; Lin, D.J.; Xiao, R.Z.; Huang, R.W.; Huang H.Q.; Liu P.Q.; Liu J.J. Down-regulation of telomerase activity and activation of caspase-3 are responsible for tanshinone I-induced apoptosis in monocyte leukemia cells in vitro. Int. J. Mol. Sci., 2010, 11 (6),2267-2280.
251. Tang, C.; Xue, H.L.; Huang, H.B.; Wang, X.G. Tanshinone IIA inhibits constitutive STAT3 activation, suppresses proliferation, and induces apoptosis in rat C6 glioma cells. Neurosci. Lett., 2010, 470 (2),126-129.
252. Lee, W.Y.; Cheung, C.C.; Liu, K.W.; Fung, K.P.; Wong, J.; Lai, P.B.; Yeung, J.H. Cytotoxic effects of tanshinones from Salvia miltiorrhiza on doxorubicin-resistant human liver cancer cells. J. Nat. Prod., 2010, 73 (5),854-859.
253. Pan, H.; Li, D.; Fang, F.; Chen, D.; Qi, L.; Zhang, R.; Xu, T.; Sun, H. Salvianolic acid A Demonstrates Cardioprotective Effects in Rat Hearts and Cardiomyocytes Following Ischemia/Reperfusion Injury. J. Cardiovasc. Pharmacol., 2011, 58(5), 535-542
254. Pan, C.; Lou, L.; Huo, Y.; Singh, G.; Chen, M.; Zhang, D.; Wu, A.; Zhao, M.; Wang S.; Li J. Salvianolic acid B and tanshinone IIA attenuate myocardial ischemia injury in mice by NO production through multiple pathways. Ther. Adv. Cardiovasc. Dis., 2011, 5 (2),99-111.
255. Fan, H.Y.; Fu, F.H.; Yang, M.Y.; Xu, H.; Zhang, A.H.; Liu, K. Antiplatelet and antithrombotic activities of salvianolic acid A. Thromb. Res., 2010, 126 (1),e17-22.
256. Yang, T.L.; Lin, F.Y.; Chen, Y.H.; Chiu, J.J.; Shiao, M.S.; Tsai, C.S.; Lin, S.J.; Chen, Y.L. Salvianolic acid B inhibits low-density lipoprotein oxidation and neointimal hyperplasia in endotheliumdenuded hypercholesterolaemic rabbits. J. Sci. Food Agric., 2011, 91 (1),134-141.
257. Tang, C.; Xue, H.; Bai, C.; Fu, R.; Wu, A. The effects of Tanshinone IIA on blood-brain barrier and brain edema after transient middle cerebral artery occlusion in rats. Phytomedicine, 2010, 17 (14),1145-1149.
258. Wang, W.; Zheng, L.L.; Wang, F.; Hu, Z.L.; Wu, W.N.; Gu, J.; Chen, J.G. Tanshinone IIA attenuates neuronal damage and the impairment of long-term potentiation induced by hydrogen peroxide. J. Ethnopharmacol., 2011, 134 (1),147-155.
259. Shen, J.L.; Chen, Y.S.; Lin, J.Y.; Tien, Y.C.; Peng, W.H.; Kuo, C.H.; Tzang, B.S.; Wang, H.L.; Tsai, F.J.; Chou, M.C.; Huang, C.Y.; Lin, C.C. Neuron Regeneration and Proliferation Effects of Danshen and Tanshinone IIA. Evid. Based. Complement. Alternat. Med., 2011, 2011,378907.
260. Liu, Y.; Li, X.; Li, Y.; Wang, L.; Xue, M. Simultaneous determination of danshensu, rosmarinic acid, cryptotanshinone, tanshinone IIA, tanshinone I and dihydrotanshinone I by liquid chromatographic- mass spectrometry and the application to pharmacokinetics in rats. J. Pharm. Biomed. Anal., 2010, 53 (3), 698-704.
261. Park, E.J.; Ji, H.Y.; Kim, N.J.; Song, W.Y.; Kim, Y.H.; Kim, Y.C.; Sohn, D.H.; Lee, H.S. Simultaneous determination of tanshinone I, dihydrotanshinone I, tanshinone IIA and cryptotanshinone in rat plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study of a standardized fraction of Salvia miltiorrhiza, PF2401-SF. Biomed. Chromatogr., 2008, 22 (5),548-555.
262. Wang, L.; Zhang, Q.; Li, X.; Lu, Y.; Xue, Z.; Xuan, L.; Wang, Y. Pharmacokinetics and metabolism of lithospermic acid by LC/MS/MS in rats. Int. J. Pharm., 2008, 350 (1-2),240-246.
263. Li, W.; Li, Z.W.; Han, J.P.; Li, X.X.; Gao, J.; Liu, C.X. Determination and pharmacokinetics of danshensu in rat plasma after oral administration of danshen extract using liquid chromatography/tandem mass spectrometry. Eur. J. Drug Metab. Pharmacokinet., 2008, 33 (1),9-16.
264. Zhou, L.; Chow, M.S.; Zuo, Z. Effect of sodium caprate on the oral absorptions of danshensu and salvianolic acid B. Int. J. Pharm., 2009, 379 (1),109-118.
265. Wu, Y.T.; Chen, Y.F.; Hsieh, Y.J.; Jaw, I.; Shiao, M.S.; Tsai, T.H. Bioavailability of salvianolic acid B in conscious and freely moving rats. Int. J. Pharm., 2006, 326 (1-2),25-31.
266. Pan, Y.; Bi, H.C.; Zhong, G.P.; Chen, X.; Zuo, Z.; Zhao, L.Z.; Gu, L.Q.; Liu, P.Q.; Huang, Z.Y.; Zhou, S.F.; Huang, M. Pharmacokinetic characterization of hydroxylpropyl-beta-cyclodextrinincluded complex of cryptotanshinone, an investigational cardiovascular drug purified from Danshen (Salvia miltiorrhiza). Xenobiotica., 2008, 38 (4),382-398.
267. Gao, D.Y.; Han, L.M.; Zhang, L.H.; Fang, X.L.; Wang, J.X. Bioavailability of salvianolic acid B and effect on blood viscosities after oral administration of salvianolic acids in beagle dogs. Arch. Pharm. Res., 2009, 32 (5),773-779.
268. Zhang, Y.; Akao, T.; Nakamura, N.; Duan, C.L.; Hattori, M.; Yang, X.W.; Liu, J.X. Extremely low bioavailability of magnesium lithospermate B, an active component from Salvia miltiorrhiza, in rat. Planta Med., 2004, 70 (2),138-142.
269. Shen, Y.; Wang, X.; Xu, L.; Liu, X.; Chao, R. Characterization of metabolites in rat plasma after intravenous administration of salvianolic acid A by liquid chromatography/time-of-flight mass spectrometry and liquid chromatography/ion trap mass spectrometry. Rapid. Commun. Mass. Spectrom., 2009, 23 (12),1810-1816.
270. Liu, J.; Wu, J.; Wang, X.; Cai, Z. Study of the phase I and phase II metabolism of a mixture containing multiple tanshinones using liquid chromatography/tandem mass spectrometry. Rapid. Commun. Mass. Spectrom., 2007, 21 (18),2992-2998.
271. Wang, Q.; Hao, H.; Zhu, X.; Yu, G.; Lai, L.; Liu, Y.; Wang, Y.; Jiang, S.; Wang, G. Regioselective glucuronidation of tanshinone iia after quinone reduction: identification of human UDPglucuronosyltransferases, species differences, and interaction potential. Drug Metab. Dispos., 2010, 38 (7),1132-1140.
272. Hao, H.; Wang, G.; Cui, N.; Li, J.; Xie, L.; Ding, Z. Identification of a novel intestinal first pass metabolic pathway: NQO1 mediated quinone reduction and subsequent glucuronidation. Curr. Drug Metab., 2007, 8 (2),137-149.
273. Xu, M.; Guo, H.; Han, J.; Sun, S.F.; Liu, A.H.; Wang, B.R.; Ma, X.C.; Liu, P.; Qiao, X.; Zhang, Z.C.; Guo, D.A. Structural characterization of metabolites of salvianolic acid B from Salvia miltiorrhiza in normal and antibiotic-treated rats by liquid chromatography- mass spectrometry. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 2007, 858 (1-2),184-198.
274. Cui, L.; Chan, W.; Wu, J.L.; Jiang, Z.H.; Chan, K.; Cai, Z. High performance liquid chromatography-mass spectrometry analysis for rat metabolism and pharmacokinetic studies of lithospermic acid B from danshen. Talanta, 2008, 75 (4),1002-1007.
275. Li, X.; Yu, C.; Lu, Y.; Gu, Y.; Lu, J.; Xu, W.; Xuan, L.; Wang, Y. Pharmacokinetics, tissue distribution, metabolism, and excretion of depside salts from Salvia miltiorrhiza in rats. Drug Metab. Dispos., 2007, 35 (2),234-239.
276. Wang, X.; Yeung, J.H. Effects of Salvia miltiorrhiza Extract on the Liver CYP3A Activity in Humans and Rats. Phytother. Res., 2011, 25(11),1653-1659.
277. Wang, X.; Yeung, J.H. Inhibitory effect of tanshinones on rat CYP3A2 and CYP2C11 activity and its structure-activity relationship. Fitoterapia, 2011, 82 (4),539-545.
278. Zhang, R.; Sun, J.; Ma, L.; Wu, X.; Pan, G.; Hao, H.; Zhou, F.; A, J.; Liu, C.; Ai, H.; Shang, L.; Gao, H.; Peng, Y.; Wan, P.; Wu, H.; Wang, G. Induction of cytochromes P450 1A1 and 1A2 by tanshinones in human HepG2 hepatoma cell line. Toxicol. Appl. Pharmacol., 2011, 252 (1),18-27.
279. Wang, X.; Cheung, C.M.; Lee, W.Y.; Or, P.M.; Yeung, J.H. Major tanshinones of Danshen (Salvia miltiorrhiza) exhibit different modes of inhibition on human CYP1A2, CYP2C9, CYP2E1 and CYP3A4 activities in vitro. Phytomedicine, 2010, 17 (11),868-875.
280. Jinping, Q.; Peiling, H.; Yawei, L.; Abliz, Z. Effects of the aqueous extract from Salvia miltiorrhiza Bge on the pharmacokinetics of diazepam and on liver microsomal cytochrome P450 enzyme activity in rats. J. Pharm. Pharmacol., 2003, 55 (8),1163-1167.
281. Tulkens, P.M. Intracellular pharmacokinetics and localization of antibiotics as predictors of their efficacy against intraphagocytic infections. Scand. J. Infect. Dis. Suppl., 1990, 74,209-217.
282. Krishan, A.; Fitz, C.M.; Andritsch, I. Drug retention, efflux, and resistance in tumor cells. Cytometry, 1997, 29 (4),279-285.
283. Duvvuri, M.; Krise, J.P. Intracellular drug sequestration events associated with the emergence of multidrug resistance: a mechanistic review. Front Biosci., 2005, 10,1499-1509.
284. Hoffmann, J.; Vitale, I.; Buchmann, B.; Galluzzi, L.; Schwede, W.; Senovilla, L.; Skuballa, W.; Vivet, S.; Lichtner, R.B.; Vicencio, J.M.; Panaretakis, T.; Siemeister, G.; Lage, H.; Nanty, L.; Hammer, S.; Mittelstaedt, K.; Winsel, S.; Eschenbrenner, J.; Castedo, M.; Demarche, C.; Klar, U.; Kroemer, G. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res., 2008, 68 (13),5301-5308.
285. Siebert, G.A.; Hung, D.Y.; Chang, P.; Roberts, M.S. Ion-trapping, microsomal binding, and unbound drug distribution in the hepatic retention of basic drugs. J. Pharmacol. Exp. Ther., 2004, 308 (1),228-235.
286. Barcia-Macay, M.; Mouaden, F.; Mingeot-Leclercq, M.P.; Tulkens, P.M.; Van Bambeke, F. Cellular pharmacokinetics of telavancin, a novel lipoglycopeptide antibiotic, and analysis of lysosomal changes in cultured eukaryotic cells (J774 mouse macrophages and rat embryonic fibroblasts). J. Antimicrob. Chemother., 2008, 61 (6),1288-1294.
287. Jung, L.L.; Zamboni, W.C. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it? Drug Resist. Updat., 2001, 4 (4),273-288.
288. Zhou, F.; Zhang, J.; Li, P.; Niu, F.; Wu, X.; Wang, G.; Roberts, M.S. Toward a new age of cellular pharmacokinetics in drug discovery. Drug Metab. Rev., 2011, 43 (3),335-345.
289. Richly, H.; Grubert, M.; Scheulen, M.E.; Hilger, R.A. Plasma and cellular pharmacokinetics of doxorubicin after intravenous infusion of Caelyx/Doxil in patients with hematological tumors. Int. J. Clin. Pharmacol. Ther., 2009, 47 (1),55-57.
290. Stepanic, V.; Kostrun, S.; Malnar, I.; Hlevnjak, M.; Butkovic, K.; Caleta, I.; Duksi, M.; Kragol, G.; Makaruha-Stegic, O.; Mikac, L.; Ralic, J.; Tatic, I.; Tavcar, B.; Valko, K.; Zulfikari, S.; Munic, V. Modeling Cellular Pharmacokinetics of 14- and 15-Membered Macrolides with Physicochemical Properties. J. Med. Chem., 2011.
291. Zuco, V.; Supino, R.; Favini, E.; Tortoreto, M.; Cincinelli, R.; Croce, A.C.; Bucci, F.; Pisano, C.; Zunino, F. Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma. Biochem. Pharmacol., 2010, 79 (4),535-541.
292. Van Bambeke, F.; Carryn, S.; Seral, C.; Chanteux, H.; Tyteca, D.; Mingeot-Leclercq, M.P.; Tulkens, P.M. Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. Antimicrob. Agents Chemother., 2004, 48 (8),2853-2860.
293. Hung, D.Y.; Siebert, G.A.; Chang, P.; Roberts, M.S. Hepatic pharmacokinetics of taurocholate in the normal and cholestatic rat liver. Br. J. Pharmacol., 2005, 145 (1),57-65.
294. Zhang, X.; Shedden, K.; Rosania, G.R. A cell-based molecular transport simulator for pharmacokinetic prediction and cheminformatic exploration. Mol. Pharm., 2006, 3 (6),704-716.
295. Sanchez, C.P.; Stein, W.D.; Lanzer, M. Dissecting the components of quinine accumulation in Plasmodium falciparum. Mol. Microbiol., 2008, 67 (5),1081-1093.
296. Pooley, S.; Fatih, F.A.; Krishna, S.; Gerisch, M.; Haynes, R.K.; Wong, H.N.; Staines, H.M. Artemisone uptake in Plasmodium falciparum- infected erythrocytes. Antimicrob. Agents Chemother., 2011, 55 (2),550-556.
297. Liu, Y.; Lok, C.N.; Ko, B.C.; Shum, T.Y.; Wong, M.K.; Che, C.M. Subcellular localization of a fluorescent artemisinin derivative to endoplasmic reticulum. Org. Lett., 2010, 12 (7),1420-1423.
298. Lee, J.Y.; Bae, K.H.; Kim, J.S.; Nam, Y.S.; Park, T.G. Intracellular delivery of paclitaxel using oil-free, shell cross-linked HSA - Multi-armed PEG nanocapsules. Biomaterials, 2011, 32(33), 8635-8644.
299. Harada, Y.; Dai, P.; Yamaoka, Y.; Ogawa, M.; Tanaka, H.; Nosaka, K.; Akaji, K.; Takamatsu, T. Intracellular dynamics of topoisomerase I inhibitor, CPT-11, by slit-scanning confocal Raman microscopy. Histochem. Cell Biol., 2009, 132 (1),39-46.
300. Zhao, Y.; Gao, J.; Sun, X.; Chen, H.; Wu, L.; Liang, W. Enhanced nuclear delivery and cytotoxic activity of hydroxycamptothecin using o/w emulsions. J. Pharm. Pharm. Sci., 2007, 10 (1),61-70.
301. Petrangolini, G.; Supino, R.; Pratesi, G.; Dal Bo, L.; Tortoreto, M.; Croce, A.C.; Misiano, P.; Belfiore, P.; Farina, C.; Zunino, F. Effect of a novel vacuolar-H+-ATPase inhibitor on cell and tumor response to camptothecins. J. Pharmacol. Exp. Ther., 2006, 318 (3),939-946.
302. Mukai, R.; Shirai, Y.; Saito, N.; Yoshida, K.; Ashida, H. Subcellular localization of flavonol aglycone in hepatocytes visualized by confocal laser scanning fluorescence microscope. Cytotechnology, 2009, 59 (3),177-182.
303. Arredondo, F.; Echeverry, C.; Abin-Carriquiry, J.A.; Blasina, F.; Antunez, K.; Jones, D.P.; Go, Y.M.; Liang, Y.L.; Dajas, F. After cellular internalization, quercetin causes Nrf2 nuclear translocation, increases glutathione levels, and prevents neuronal death against an oxidative insult. Free Radic. Biol. Med., 2010, 49 (5),738-747.
304. Lemaire, S.; Tulkens, P.M.; Van Bambeke, F. Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils. Antimicrob. Agents Chemother., 2010, 54 (6),2540-2548.
305. Shen, F.; Bailey, B.J.; Chu, S.; Bence, A.K.; Xue, X.; Erickson, P.; Safa, A.R.; Beck, W.T.; Erickson, L.C. Dynamic assessment of mitoxantrone resistance and modulation of multidrug resistance by valspodar (PSC833) in multidrug resistance human cancer cells. J. Pharmacol. Exp. Ther., 2009, 330 (2),423-429.
306. Shen, F.; Chu, S.; Bence, A.K.; Bailey, B.; Xue, X.; Erickson, P.A.; Montrose M.H.; Beck W.T.; Erickson L.C. Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J. Pharmacol. Exp. Ther., 2008, 324 (1),95-102.
307. Duvvuri, M.; Feng, W.; Mathis, A.; Krise, J.P. A cell fractionation approach for the quantitative analysis of subcellular drug disposition. Pharm. Res., 2004, 21 (1),26-32.
308. Dopp, E.; von Recklinghausen, U.; Diaz-Bone, R.; Hirner, A.V.; Rettenmeier, A.W. Cellular uptake, subcellular distribution and toxicity of arsenic compounds in methylating and non-methylating cells. Environ. Res., 2010, 110 (5),435-442.
309. Zhou, S.; Gao, Y.; Jiang, W.; Huang, M.; Xu, A.; Paxton J.W. Interactions of herbs with cytochrome P450. Drug Metab. Rev., 2003, 35 (1),35-98.
310. Zhou, S.; Lim L.Y.; Chowbay, B. Herbal modulation of Pglycoprotein. Drug Metab. Rev., 2004, 36 (1),57-104.
311. Marchetti, S.; Mazzanti, R.; Beijnen, J.H.; Schellens, J.H. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist, 2007, 12 (8),927-941.
312. Delgoda, R.; Westlake, A.C. Herbal interactions involving cytochrome p450 enzymes: a mini review. Toxicol. Rev., 2004, 23 (4),239-249.
313. Yang, X.X.; Hu, Z.P.; Duan, W.; Zhu, Y.Z.; Zhou, S.F. Drug-herb interactions: eliminating toxicity with hard drug design. Curr. Pharm. Des., 2006, 12 (35),4649-4664.
314. Larsen, A.K.; Escargueil, A.E.; Skladanowski, A. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol. Ther., 2000, 85 (3),217-229.
315. van Montfoort, J.E.; Hagenbuch, B.; Groothuis, G.M.; Koepsell, H.; Meier, P.J.; Meijer, D.K. Drug uptake systems in liver and kidney. Curr. Drug Metab., 2003, 4 (3),185-211.
316. Schinkel, A.H.; Jonker, J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev., 2003, 55 (1),3-29.
317. Molinari, A.; Calcabrini, A.; Meschini, S.; Stringaro, A.; Crateri, P.; Toccacieli, L.; Marra, M.; Colone, M.; Cianfriglia, M.; Arancia, G. Subcellular detection and localization of the drug transporter Pglycoprotein in cultured tumor cells. Curr. Protein. Pept. Sci., 2002, 3 (6),653-670.
318. Rajagopal, A.; Simon, S.M. Subcellular localization and activity of multidrug resistance proteins. Mol. Biol. Cell, 2003, 14 (8),3389-3399.
319. Porcelli, L.; Lemos, C.; Peters, G.J.; Paradiso, A.; Azzariti, A. Intracellular trafficking of MDR transporters and relevance of SNPs. Curr. Top. Med. Chem., 2009, 9 (2),197-208.
320. Baldini, N.; Scotlandi, K.; Serra, M.; Shikita, T.; Zini, N.; Ognibene, A.; Santi, S.; Ferracini, R.; Maraldi, N.M. Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution. Eur. J. Cell Biol., 1995, 68 (3),226-239.
321. Munteanu, E.; Verdier, M.; Grandjean-Forestier, F.; Stenger, C.; Jayat-Vignoles, C.; Huet, S.; Robert, J.; Ratinaud, M.H. Mitochondrial localization and activity of P-glycoprotein in doxorubicinresistant K562 cells. Biochem. Pharmacol., 2006, 71 (8),1162-1174.
322. Gong, Y.; Duvvuri M.; Krise, J.P. Separate roles for the Golgi apparatus and lysosomes in the sequestration of drugs in the multidrug-resistant human leukemic cell line HL-60. J. Biol. Chem., 2003, 278 (50),50234-50239.
323. Bour-Dill, C.; Gramain, M.P.; Merlin, J.L.; Marchal, S.; Guillemin, F. Determination of intracellular organelles implicated in daunorubicin cytoplasmic sequestration in multidrug-resistant MCF-7 cells using fluorescence microscopy image analysis. Cytometry, 2000, 39 (1),16-25.
324. Ferrao, P.; Sincock, P.; Cole, S.; Ashman, L. Intracellular P-gp contributes to functional drug efflux and resistance in acute myeloid leukaemia. Leuk. Res., 2001, 25 (5),395-405.
325. Solazzo, M.; Fantappie, O.; Lasagna, N.; Sassoli, C.; Nosi, D.; Mazzanti, R. P-gp localization in mitochondria and its functional characterization in multiple drug-resistant cell lines. Exp. Cell Res., 2006, 312 (20),4070-4078.
326. Solazzo, M.; Fantappie, O.; D'Amico, M.; Sassoli, C.; Tani, A.; Cipriani, G.; Bogani, C.; Formigli, L.; Mazzanti, R. Mitochondrial expression and functional activity of breast cancer resistance protein in different multiple drug-resistant cell lines. Cancer Res., 2009, 69 (18),7235-7242.
327. Zhang, J.; Zhou, F.; Wu, X.; Zhang, X.; Chen, Y.; Zha, B.S.; Niu, F.; Lu, M.; Hao, G.; Sun, Y.; Sun, J.; Peng, Y.; Wang, G. Cellular Pharmacokinetic Mechanisms of Adriamycin Resistance and Its Modulation by 20(S)-Ginsenoside Rh2 in MCF-7/Adr Cells. Br. J. Pharmacol., 2012, 165 (1),120-134.
328. Molinari, A.; Calcabrini, A.; Meschini, S.; Stringaro, A.; Del Bufalo, D.; Cianfriglia, M.; Arancia, G. Detection of P-glycoprotein in the Golgi apparatus of drug-untreated human melanoma cells. Int. J. Cancer, 1998, 75 (6),885-893.
329. Lewis, D.F.; Ito, Y. Human CYPs involved in drug metabolism: structures, substrates and binding affinities. Expert. Opin. Drug Metab. Toxicol., 2010, 6 (6),661-674.
330. Iyanagi, T. Molecular mechanism of phase I and phase II drugmetabolizing enzymes: implications for detoxification. Int. Rev. Cytol., 2007, 260,35-112.
331. Anzenbacher, P.; Anzenbacherova, E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol. Life Sci., 2001, 58 (5-6),737-747.
332. Werck-Reichhart D.; Feyereisen R. Cytochromes P450: a success story. Genome. Biol., 2000, 1 (6),REVIEWS3003.
333. Sakaguchi, M.; Mihara, K.; Sato, R. Signal recognition particle is required for co-translational insertion of cytochrome P-450 into microsomal membranes. Proc. Natl. Acad. Sci. U. S. A., 1984, 81 (11),3361-3364.
334. Omura, T. Mitochondrial P450s. Chem. Biol. Interact., 2006, 163 (1-2),86-93.
335. Ahn, T.; Yun, C.H. Molecular mechanisms regulating the mitochondrial targeting of microsomal cytochrome P450 enzymes. Curr. Drug Metab., 2010, 11 (10),830-838.
336. Neve E.P.; Ingelman-Sundberg M. Intracellular transport and localization of microsomal cytochrome P450. Anal. Bioanal. Chem., 2008, 392 (6),1075-1084.
337. King, C.D.; Rios, G.R.; Green, M.D.; Tephly, T.R. UDPglucuronosyltransferases. Curr. Drug Metab., 2000, 1 (2),143-161.
338. Lind, T.; Lindahl, U.; Lidholt, K. Biosynthesis of heparin/heparan sulfate. Identification of a 70-kDa protein catalyzing both the D glucuronosyl- and the N-acetyl-D-glucosaminyltransferase reactions. J. Biol. Chem., 1993, 268 (28),20705-20708.
339. Radominska-Pandya, A.; Pokrovskaya, I.D.; Xu, J.; Little, J.M.; Jude, A.R.; Kurten, R.C.; Czernik, P.J. Nuclear UDPglucuronosyltransferases: identification of UGT2B7 and UGT1A6 in human liver nuclear membranes. Arch. Biochem. Biophys., 2002, 399 (1),37-48.
340. Hayes, J.D.; Flanagan, J.U.; Jowsey, I.R. Glutathione transferases. Annu. Rev. Pharmacol. Toxicol., 2005, 45,51-88.
341. Soboll, S.; Grundel, S.; Harris, J.; Kolb-Bachofen, V.; Ketterer, B.; Sies, H. The content of glutathione and glutathione S-transferases and the glutathione peroxidase activity in rat liver nuclei determined by a non-aqueous technique of cell fractionation. Biochem. J., 1995, 311 ,889-894.
342. Raza, H.; Robin, M.A.; Fang, J.K.; Avadhani, N.G. Multiple isoforms of mitochondrial glutathione S-transferases and their differential induction under oxidative stress. Biochem. J., 2002, 366 ,45-55.
343. Petit, E.; Michelet, X.; Rauch, C.; Bertrand-Michel, J.; Terce, F.; Legouis, R.; Morel, F. Glutathione transferases kappa 1 and kappa 2 localize in peroxisomes and mitochondria, respectively, and are involved in lipid metabolism and respiration in Caenorhabditis elegans. FEBS. J., 2009, 276 (18),5030-5040.
344. Morel, F.; Aninat C. The glutathione transferase kappa family. Drug Metab. Rev., 2011, 43 (2),281-291.
345. Kikuchi, Y.; Sasa, H.; Kita, T.; Hirata, J.; Tode, T.; Nagata, I. Inhibition of human ovarian cancer cell proliferation in vitro by ginsenoside Rh2 and adjuvant effects to cisplatin in vivo. Anticancer Drugs, 1991, 2 (1),63-67.
346. Jia, W.W.; Bu, X.; Philips, D.; Yan, H.; Liu, G.; Chen, X.; Bush, J.A.; Li, G. Rh2, a compound extracted from ginseng, hypersensitizes multidrug-resistant tumor cells to chemotherapy. Can. J. Physiol. Pharmacol., 2004, 82 (7),431-437.
347. Xie, X.; Eberding, A.; Madera, C.; Fazli, L.; Jia, W.; Goldenberg, L.; Gleave, M.; Guns, E.S. Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models. J. Urol., 2006, 175 (5),1926-1931.
348. Zhang, J.; Zhou, F.; Wu, X.; Gu, Y.; Ai, H.; Zheng, Y.; Li, Y.; Zhang, X.; Hao, G.; Sun J.; Peng Y.; Wang G. 20(S)-ginsenoside rh2 noncompetitively inhibits p-glycoprotein in vitro and in vivo: a case for herb-drug interactions. Drug Metab. Dispos., 2010, 38 (12),2179-2187.
349. Wang, X.; Wei, Y.; Yuan, S.; Liu, G.; Lu, Y.; Zhang, J.; Wang, W. Potential anticancer activity of tanshinone IIA against human breast cancer. Int. J. Cancer, 2005, 116 (5),799-807.
350. Wang, J.; Wang, X.; Jiang, S.; Yuan, S.; Lin, P.; Zhang, J.; Lu, Y.; Wang, Q.; Xiong, Z.; Wu, Y.; Ren, J.; Yang, H. Growth inhibition and induction of apoptosis and differentiation of tanshinone IIA in human glioma cells. J. Neurooncol., 2007, 82 (1),11-21.
351. Dai, Z.K.; Qin, J.K.; Huang, J.E.; Luo, Y.; Xu, Q.; Zhao, H.L. Tanshinone IIA activates calcium-dependent apoptosis signaling pathway in human hepatoma cells. J. Nat. Med., 2012, 66(1), 192-201.